|
Q3 FY2026
As of Sep 30, 2026
|
Q2 FY2026
As of Jun 30, 2026
|
Q1 FY2026
As of Mar 31, 2026
|
Q4 FY2025
As of Dec 31, 2025
|
Q3 FY2025
As of Sep 30, 2025
|
Q2 FY2025
As of Jun 30, 2025
|
Q1 FY2025
As of Mar 31, 2025
|
|
|---|---|---|---|---|---|---|---|
| ASSETS | |||||||
| Current assets: | |||||||
| Due from Sponsor | |||||||
| Cash and cash equivalents | |||||||
| Prepaid insurance | |||||||
| Prepaid expenses and other current assets | |||||||
| Total current assets | |||||||
| Deferred offering costs | |||||||
| Marketable securities held in Trust Account | |||||||
| Long-term prepaid insurance | |||||||
| TOTAL ASSETS | |||||||
| LIABILITIES AND SHAREHOLDERS’ DEFICIT | |||||||
| Current liabilities: | |||||||
| Accrued expenses | |||||||
| Accrued offering costs | |||||||
| Due to related party | |||||||
| Promissory note - related party | |||||||
| Total current liabilities | |||||||
| Deferred underwriting fee payable | |||||||
| Total Liabilities | |||||||
| Class A ordinary shares subject to possible redemption, 17,250,000 shares at redemption value of $10.53 and $10.27 per share at September 30, 2026 and December 31, 2025, respectively | |||||||
| Shareholders’ Deficit | |||||||
| Ordinary shares, value | |||||||
| Additional paid-in capital | |||||||
| Accumulated deficit | |||||||
| Class B Ordinary Shares | |||||||
| Total accumulated deficit | |||||||
| Total Shareholders’ Deficit | |||||||
| TOTAL LIABILITIES AND SHAREHOLDERS’ DEFICIT |
Loading...